-
Graft Versus Host Disease and Transplant Complications
6012552
global
1
0.5
0.5
Clinical Review
0
1
Hematology-Oncology2023-09-28 20:00:00
Are you up to date on recent advances in GvHD prevention and treatment?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Acute Leukemia
5005273
global
1
0.75
2
0.75
3
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-09-28 20:00:00
Drs DiNardo, Erba, and Zeidan discuss recent data on the most promising emerging therapies in acute myeloid leukemia (AML).
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Chronic Myeloid Leukemia
1552
global
1
0.75
9
0.75
2
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-09-28 20:00:00
Are you and your patients sharing the decision-making about CML treatments?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Skin Cancer
56
global
1
0.75
2
0.75
3
0.75
0.75
Commentary
0
1
Hematology-Oncology2023-09-28 20:00:00
Do you know your role on the healthcare team in the care of patients with nonmelanoma skin cancer (NMSC)?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Breast Cancer
840
global
1
1.0
9
1.0
1.0
Commentary
0
1
Hematology-Oncology2023-09-28 20:00:00
What recommendations do you make for patients with borderline risk of recurrence in the curative setting?
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Skin Cancer
56
global
1
0.25
9
0.25
0.25
Roundtable
0
1
Hematology-Oncology2023-09-27 20:00:00
Did you know that the multidisciplinary team is key when considering systemic immunotherapy for patients with nonmelanoma skin cancer?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Graft Versus Host Disease and Transplant Complications
6012552
global
1
0.5
0.5
Clinical Review
0
1
Hematology-Oncology2023-09-28 20:00:00
Are you up to date on recent advances in GvHD prevention and treatment?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Acute Leukemia
5005273
global
1
0.75
2
0.75
3
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-09-28 20:00:00
Drs DiNardo, Erba, and Zeidan discuss recent data on the most promising emerging therapies in acute myeloid leukemia (AML).
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Chronic Myeloid Leukemia
1552
global
1
0.75
9
0.75
2
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-09-28 20:00:00
Are you and your patients sharing the decision-making about CML treatments?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Skin Cancer
56
global
1
0.75
2
0.75
3
0.75
0.75
Commentary
0
1
Hematology-Oncology2023-09-28 20:00:00
Do you know your role on the healthcare team in the care of patients with nonmelanoma skin cancer (NMSC)?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Revenue and Practice Management
3029345
global
1
0.5
9
0.5
2
0.5
3
0.5
8
0.5
0.5
Clinical Brief
0
1
Family Medicine/Primary Care2023-09-29 00:00:00
Learn about the latest developments in family medicine: alopecia areata, glaucoma, and breast cancer.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Breast Cancer
840
global
1
1.0
9
1.0
1.0
Commentary
0
1
Hematology-Oncology2023-09-28 20:00:00
What recommendations do you make for patients with borderline risk of recurrence in the curative setting?
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Skin Cancer
56
global
1
0.25
9
0.25
0.25
Roundtable
0
1
Hematology-Oncology2023-09-27 20:00:00
Did you know that the multidisciplinary team is key when considering systemic immunotherapy for patients with nonmelanoma skin cancer?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Social Determinants of Health
6010999
global
1
0.5
9
0.5
2
0.5
3
0.5
8
0.5
0.5
Clinical Review
0
2
Hematology-Oncology2023-09-28 00:00:00
Do you know how to talk to your patients about cancer care costs?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Chronic Lymphocytic Leukemia
1551
global
1
0.25
9
0.25
0.25
Roundtable
0
1
Hematology-Oncology2023-09-26 20:00:00
Do you know how to assess a patient for cardiovascular risk before starting a Bruton tyrosine kinase (BTK) inhibitor?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Biologic Therapy
5000033
global
1
0.75
9
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-09-26 20:00:00
Did you know that thrombotic microangiopathy (TMA) is characterized by the presence of thrombocytopenia, microangiopathic hemolytic anemia, and evidence of organ damage?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Non-Small Cell Lung Cancer
3004986
global
1
0.5
9
0.5
0.5
Clinical Review
0
1
Hematology-Oncology2023-09-27 00:00:00
Get expert insight on the latest data from the international lung conference in Singapore.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Palliative Care
3029326
global
1
0.25
9
0.25
2
0.25
8
0.25
0.25
Clinical Review
0
2
Anesthesiology2023-09-26 00:00:00
Did you know that hospice care is not limited to patients with cancer or those whose death is very imminent?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Lung Cancer
5000186
global
1
1.0
9
1.0
1.0
Clinical Case
0
1
Hematology-Oncology2023-09-24 20:00:00
Providing individualized care for patients with lung cancer
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Lung Cancer
5000186
global
2
0.5
0.5
Commentary
0
1
Hematology-Oncology2023-09-21 20:00:00
Do you know how to best manage your patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Chronic Lymphocytic Leukemia
1551
global
1
0.75
9
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-09-21 20:00:00
What does the latest evidence say about how to use Bruton tyrosine kinase (BTK) inhibitors in the clinic for patients with chronic lymphocytic leukemia (CLL)?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Breast Cancer
840
global
1
0.25
9
0.25
0.25
Roundtable
0
1
Hematology-Oncology2023-09-20 20:00:00
How do we treat patients who need beyond third-line treatment for metastatic HER2-positive breast cancer? Drs Mahtani and Hamilton discuss how to manage these patients.
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Chronic Lymphocytic Leukemia
1551
global
1
0.25
9
0.25
0.25
Clinical Review
0
1
Hematology-Oncology2023-09-21 00:00:00
Do you know how to effectively integrate Bruton tyrosine kinase (BTK) inhibitors into the care of your patients with chronic lymphocytic leukemia (CLL)?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Biologic Therapy
5000033
global
1
1.0
9
1.0
1.0
Journal Article
0
1
Hematology-Oncology2023-09-20 20:00:00
A database study suggests that older patients with diffuse large B-cell lymphoma need more accessible, effective, and tolerable therapy.
1.0ABIM MOC
1.0CME/CE
60MIN
Save
